BLUE BELL, Pa.--(BUSINESS WIRE)--VGX Pharmaceuticals announced the submission of a Device Master File (MAF) to the U.S. Food and Drug Administration (FDA) for its patented CELLECTRA™ adaptive constant current electroporation device. The Company has been developing the CELLECTRA™ electroporator as its lead clinical medical device for delivering DNA vaccine and therapy products. Numerous preclinical efficacy studies have shown that delivery of DNA-based product candidates with the CELLECTRA™ device optimizes DNA uptake and its subsequent expression in the target tissue, and results in enhanced immune responses in animals.
